Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

C. Buske*, M. Dreyling, A. Alvarez-Larrán, J. Apperley, L. Arcaini, C. Besson, L. Bullinger, P. Corradini, M. Giovanni Della Porta, M. Dimopoulos, S. D'Sa, H. T. Eich, R. Foà, P. Ghia, M. G. da Silva, J. Gribben, R. Hajek, C. Harrison, M. Heuser, B. KiesewetterJ. J. Kiladjian, N. Kröger, P. Moreau, J. R. Passweg, F. Peyvandi, D. Rea, J. M. Ribera, T. Robak, J. F. San-Miguel, V. Santini, G. Sanz, P. Sonneveld, M. von Lilienfeld-Toal, C. Wendtner, G. Pentheroudakis, F. Passamonti*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

38 Citations (Scopus)
11 Downloads (Pure)

Abstract

Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.

Original languageEnglish
Article number100403
Number of pages20
JournalESMO Open
Volume7
Issue number2
DOIs
Publication statusPublished - Apr 2022

Bibliographical note

Funding Information: GP reports grants from Amgen, grants, personal fees and non-financial support from Merck, grants and non-financial support from AstraZeneca, grants and personal fees from Roche, grants and personal fees from BMS, grants from Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, outside the submitted work.

Publisher Copyright: © 2022 The Authors

Fingerprint

Dive into the research topics of 'Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus'. Together they form a unique fingerprint.

Cite this